Bardy Diagnostics touts validation of AI-powered AF screening tech
Bardy Diagnostics this week released information from a validation study of its novel artificial intelligence powered atrial fibrillation screening technology, touting a more than 90% sensitivity and specificity.
Data from the validation study was presented at the annual meeting of the Heart Rhythm Society in Boston.
The novel AF detection technology uses a machine learning technique employing a convolutional, feed-forward neural network trained with P-wave centric cam recordings consisting of 12 million ECG samples of persistent AF, paroxysmal AF and no AF, the Seattle-based company said.
Bardy Diagnostics said that the detection technology’s expert-validated sensitivity was 95% with a specificity of 91% for detecting atrial fibrillation events lasting 10 minutes or longer. The company touted the validation as an important milestone for its R&D pipeline of AI-powered diagnostics.
“Automated arrhythmia detection is a key component of our ongoing research and development efforts at BardyDx to advance and redefine the standard of care in cardiac monitoring. The CAM patch’s distinctive P-wave centric design and low-amplitude signal detection presents the unique opportunity to leverage its high clarity ECG signal in developing a reliable detector that surpasses less accurate methods of algorithmic approaches using RR interval variability or AI methods weighted on R-wave analysis. Diagnostic accuracy is of utmost importance in these types of automated approaches. False positive AF diagnoses can be particularly concerning given the profound harmful consequences of administering unnecessary anticoagulants, antiarrhythmic drugs, or procedural interventions. This automatic AF detector is the first step into the development of AI-driven heart rhythm diagnostics that can accurately screen a broad list of arrhythmias; the CAM patch’s powerful ability to bring detailed quality and character to the atrial ECG makes this all possible,” Bardy Diagnostics founder & CEO Dr. Gust Bardy said in a press release.